Neumora Therapeutics Inc (NMRA) FinancialsNMRAFinancialNeumora Therapeutics Inc

Evaluating the bottom line, Neumora Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -187.11%, provide a clear picture of how effectively NMRA converts its operational activities into shareholder value.

In the context of the broader market, NMRA competes directly with industry leaders such as ELDN and MGNX. With a market capitalization of $300.63M, it holds a leading position in the sector. When comparing efficiency, NMRA's gross margin of N/A stands against ELDN's N/A and MGNX's N/A. Such benchmarking helps identify whether Neumora Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported net losses, with Q2 2026 showing a loss of $43.1 million, down from $52.7 million the previous year, but still indicating ongoing financial struggles.